Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome

Korean Journal of Internal Medicine

Volumn 27, Issue 1, 2012, Pages 47-52

  Song, Hwa Young ^a   Lee, Hyo Keun ^a   Lee, June Sung ^a   Kim, Jong Yeon ^a   Yim, Yun Hyuk ^a   Song, Tae Jun ^a   Bae, Won Ki ^a   Kim, Nam Hoon ^a   Kim, Kyung Ah ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Carcinoma; Hepatitis B antibodies; Hepatocellular; Metabolic syndrome; Smoking

Indexed keywords

HEPATITIS B SURFACE ANTIBODY;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; METABOLIC SYNDROME X; OBESITY; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 84863375072     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2012.27.1.47     Document Type: Article

References (29)

1. Oh KC, Park SH, Park JC, et al. Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea? Korean J Gastroenterol 2005;45:45-51.
2. Nam SW, Jung JJ, Bae SH, et al. Clinical outcomes of delayed clearance of serum HBsAG in patients with chronic HBV infection. Korean J Intern Med 2007;22:73-76.
3. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
4. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-1354.
5. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-1832.
6. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009;115:5651-5661.
7. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009;13:631-647.
8. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-859.
9. Park KS, Lee YS, Park HW, et al. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. Korean J Intern Med 2004;19:19-26.
10. Kojima H, Sakurai S, Matsumura M, et al. Cryptogenic cirrhosis in the region where obesity is not prevalent. World J Gastroenterol 2006;12:2080-2085.
11. Korean Liver Cancer Study Group; National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391-423.
12. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
13. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141-1145.
14. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition: a Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480.
15. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005;42:218-224.
16. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163.
17. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35(5 Suppl 2):S72-S78.
18. Lee HS, Lee JH, Choi MS, Kim CY. Comparison of the incidence of hepatocellular carcinoma in HBV-and HCV-associated liver cirrhosis: a prospective study. Korean J Hepatol 1996;2:21-28.
19. Mori M, Hara M, Wada I, et al. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000;151:131-139.
20. Shimada S, Aizawa R, Abe H, Suto S, Miyakawa Y, Aizawa Y. Analysis of risk factors for hepatocellular carcinoma that is negative for hepatitis B surface antigen (HBsAg). Intern Med 2003;42:389-393.
21. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
22. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-1719.
23. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-1216.
24. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-869.
25. El-Zayadi AR. Heavy smoking and liver. World J Gastroenterol 2006;12:6098-6101.
26. El-Zayadi A, Selim O, Hamdy H, et al. Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients. World J Gastroenterol 2004;10:2963-2966.
27. Higashi Y, Tada S, Miyase S, et al. Correlation of clinical characteristics with detection of hepatitis B virus X gene in liver tissue in HBsAg-negative, and HCV-negative hepatocellular carcinoma patients. Liver 2002;22:374-379.
28. Yu MC, Yuan JM, Ross RK, Govindarajan S. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California. Hepatology 1997;25:226-228.
29. Tamori A, Nishiguchi S, Kubo S, et al. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol 2003;71:492-498.